Pfizer COVID-19 jab safe for children aged 5-11, clinical trial results show

A secondary school student receives a dose of the Pfizer vaccine against the coronavirus disease in Shah Alam, Malaysia on Sept. 20, 2021. (AP)

• The vaccine would be administered at a lower dosage than for people 12 and over

FRANKFURT: Pfizer and BioNTech on Monday said clinical trial results showed their coronavirus vaccine was “safe, well tolerated” and produced a “robust” immune response in children aged five to 11, adding that they would seek regulatory approval shortly.
The vaccine would be administered at a lower dosage than for people 12 and over, the companies said in a statement. They said they would submit their data to regulatory bodies in the European Union, the United States and around the world “as soon as possible.”